Related Experiment Video
Updated: Oct 26, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Management of type 2 diabetes in chronic kidney disease
Jefferson L Triozzi1, L Parker Gregg2,3,4, Salim S Virani5,6,7,8
1Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
Abstract:
The management of patients with type 2 diabetes and chronic kidney disease (CKD) encompasses lifestyle modifications, glycemic control with individualized HbA1c targets, and cardiovascular disease risk reduction. Metformin and sodium-glucose cotransporter-2 inhibitors are first-line agents. Glucagon-like peptide-1 receptor agonists are second-line agents. The use of other antidiabetic agents should consider patient preferences, comorbidities, drug costs, and the risk of hypoglycemia. Renin-angiotensin-aldosterone system inhibitors are strongly recommended for patients with diabetes, hypertension, and albuminuria. Non-steroidal mineralocorticoid receptor antagonists, which pose less risk of hyperkalemia than steroidal agents, are undergoing further evaluation among patients with diabetic kidney disease. Here, we discuss important advancements in the management of patients with type 2 diabetes and CKD.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Chronic Kidney Disease IV: Nursing Management
Diabetes Mellitus: Type 2 and Gestational
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations

